Fairvalue-Calculator Fairvalue-Calculator
EN DE

MindMaze Therapeutics Holding (RLFTY) Fair Value & Analysis

Healthcare · US · Market cap $66.6M

Price$0.4225
Fair Value$0.2000
Upside-52.7%
Quality95/100
Evidence: Low Range $0.1500 – $0.3000

Fair value as of: Jun 25, 2026

Analysis

MindMaze Therapeutics Holding (RLFTY) currently trades at $0.4225, while our model-based Fair Value estimate is $0.2000 — implying the stock looks roughly 52.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is MindMaze Therapeutics Holding (RLFTY) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.2000 versus a price of $0.4225 — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RLFTY?
Our 21-model fair value for MindMaze Therapeutics Holding is $0.2000 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.4225.
What is the quality score of RLFTY?
MindMaze Therapeutics Holding has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.